Pfizer has announced that it has received approval from the European health regulator to expand use of its Prevenar 13 (also known as Prevnar 13 in the US) vaccine to adults aged 18 – 49 years, bridging the gap between the 6 week – 17 years and 50+ age groups for which the vaccine is currently approved.
The European Commission's decision comes after review of Phase 3 trial of the vaccine in healthy adults aged 18-49 years.
Prevenar 13 is used to prevent infections from 13 strains of the streptococcus pneumoniae bacterium – a cause of pneumonia, ear infections and potentially fatal pneumococcal meningitis. Pneumococcal disease can affect people of all ages, although young children, older adults and individuals with certain chronic medical conditions have an increased risk. Luis Jodar, Ph.D., vice president, Vaccines Global Medicines Development Group, Pfizer said: “Adults aged 18 to 49 years with certain underlying medical conditions may benefit in particular from vaccination with Prevenar 13 because of an increased risk of pneumococcal disease."
The decision makes the world's best selling vaccine also now the only pneumococcal vaccine the EU to offer protection against invasive disease from infancy through adulthood.
How much will the expansion boost Prevenar 13 sales in the future? How big is this new market? You can leave a comment in the box below, or on LinkedIn group discussion. Want more from Vaccine Nation? Sign up to our newsletter for free here. If you want to know more about strategy and innovation in vaccines, you might be interested in attending the World Vaccine Congress Europe 2013, 16-17 October 2013, Lille.